06.08.2019

BioCentury's Emerging Company Profile

CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of neoantigens to turn “dark” tumors “light” that can be treated with immunotherapies.

More news

13.11.2026

NeoPhore strengthens leadership as it prepares to take first-in-class DNA mismatch repair inhibitor into the clinic

Marianne Bjordal appointed CEO; Judit Molnar promoted to Chief Development Officer London, UK, 13 November 2026 – NeoPhore Limited, a company …

21.04.2026

AACR 2026 and AACR Cancer Discovery Article

NeoPhore Press Release: AACR 2026 and AACR Cancer Discovery Article London UK, 21 April 2026 NeoPhore, an immuno-oncology company, announces the …

16.09.2025

NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025

NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …

Contact us at [email protected]  |  
Call us +44 (0) 330 128 9990